Skip to main content
NIH funding notice PA-17-291

HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01)

Closed on May 7, 2018.

Posted
May 17, 2017
Close date
May 7, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,526,437 in first-year total cost, median $763,219.

Most frequent study sections

  1. AIDS Clinical Studies and Epidemiology Study Section[ACE]1
  2. AIDS Molecular and Cellular Biology Study Section[AMCB]1

Most frequent institutions

  1. BRIGHAM AND WOMEN'S HOSPITAL1
  2. UNIV OF NORTH CAROLINA CHAPEL HILL1
Competing awards under PA-17-291 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2018Novel virologic and pharmacologic assays to predict clinical outcomes after first-line ART failure in sub-Saharan Africa1R01AI138801-01A1LI, JONATHANBRIGHAM AND WOMEN'S HOSPITAL, MA$853,765ACE
2018HIV Evolution Defines Virus-Host/Drug Interactions In Viremic and Aviremic People1R01AI140970-01SWANSTROM, RONALD IUNIV OF NORTH CAROLINA CHAPEL HILL, NC$672,672AMCB

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PA-17-291: HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) | ScienceDex | ConductScience